<DOC>
	<DOC>NCT02219048</DOC>
	<brief_summary>The study proposes to evaluate the safety and efficacy of PF-03715455 in moderate to severe asthma when added to standard of care and during staged withdrawal of background therapy.</brief_summary>
	<brief_title>An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma</brief_title>
	<detailed_description>Study terminated on 7th April 2015. The termination was due to business reasons. No safety or efficacy concerns contributed to the termination of the study</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Subjects with a physician documented history or diagnosis of persistent asthma (according to GINA, 2014 definition of asthma), Pre bronchodilator FEV1 of greater than or equal to 50 and less that 80% of predicted. Subjects defined as GINA Step 4 on a stable dose of either fluticasone/salmeterol combination therapy, or budesonide/formoterol combination therapy or mometasone/formoterol combination therapy. Subjects who are defined as uncontrolled as evidenced by; Juniper Asthma Control Questionnaire (5 item version, ACQ) score greater than or equal to 1.5 and less than or equal to 3.0) Subjects diagnosed with chronic pulmonary disease (COPD) and/or other chronic pulmonary diseases (eg, Occupational asthma, pulmonary fibrosis, bronchiectasis, Allergic bronchopulmonary aspergillosis (ABPA), pneumoconiosis, sarcoidosis, tuberculosis). Subjects who are current smokers.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Staged withdrawal of background therapy</keyword>
</DOC>